

Determinants of emergency department use and hospitalization among people who inject drugs: A systematic review and meta-analysis

Bahram Armoon^{a,b}, Marie-Josée Fleury^{a,b}, Mark D. Griffiths^c, Azadeh Bayani^d, Rasool Mohammadi^{e,f}, and Elaheh Ahounbar^{g,h}

^aDouglas Hospital Research Centre, Montreal, Quebec, Canada; ^bDepartment of Psychiatry, McGill University, Montreal, Quebec, Canada; ^cInternational Gaming Research Unit, Psychology Department, Nottingham Trent University, Nottingham, UK; ^dStudent Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^eSocial Determinants of Health Research Center, School of Public Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran; ^fDepartment of Biostatistics and Epidemiology, School of Public Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran; ^gOrygen, The National Center of Excellence in Youth Mental Health, University of Melbourne, Parkville, Australia; ^hCenter for Youth Mental Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia

ABSTRACT

Background: The present study aimed to identify sociodemographic characteristics, risky behaviors, type of drug use, and service use variables associated with emergency department (ED) use and hospitalization among people who inject drugs (PWID).

Methods: Studies in English published from January 1, 1995, to December 15, 2021, were searched for on *PubMed*, *Scopus*, *Cochrane*, and *Web of Science* to identify primary studies on ED use and hospitalization among PWID.

Results: After a detailed assessment of 17,348 outputs, a total of 19 studies met the eligibility criteria for inclusion in the analysis. Greater risks of ED use and hospitalization among PWID were associated with (i) a history of homelessness, (ii) HIV-positive status, and (iii) injecting drugs more than four times per day. Individuals were more likely to use the ED if they (i) had a history of physical abuse, (ii) were using cocaine and methamphetamine, and (iii) had used primary care services. Women and individuals with chronic physical illnesses were more likely to be hospitalized.

Conclusions: The present study is the first to integrate determinants related to ED use and hospitalization based on sociodemographic characteristics, risky behaviors, type of drug, and service use determinants among PWID. To reduce ED use and hospitalization among PWID, the paper also recommends various strategies could be implemented.

ARTICLE HISTORY

Received 12 April 2022
Accepted 6 April 2023

KEYWORDS

Emergency department use; hospitalization; people who inject drugs; psychoactive substances; primary care services

This is the accepted version of this following article: **Determinants of emergency department use and hospitalization among people who inject drugs: A systematic review and meta-analysis.** Journal of Substance Use 2023. <https://doi.org/10.1080/14659891.2023.2202767>.
Online ahead of print.

Determinants of emergency department use and hospitalization among people who inject drugs: A systematic review and meta-analysis

Bahram Armoon PhD^{1,2}, Marie-Josée Fleury PhD^{1,2}, Mark D. Griffiths PhD³, Azadeh Bayani MSc⁴, Rasool Mohammadi PhD^{5,6}, Elaheh Ahounbar MSc^{7,8}

¹Douglas Hospital Research Centre, Montreal, Quebec, Canada

²Department of Psychiatry, McGill University, Montreal, Quebec, Canada

³International Gaming Research Unit, Psychology Department, Nottingham Trent University, Nottingham, UK

⁴Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁵ Social Determinants of Health Research Center, School of Public Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran

⁶Department of Biostatistics and Epidemiology, School of Public Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran

⁷Orygen, The National Center of Excellence in Youth Mental Health, University of Melbourne, Parkville, VIC, Australia

⁸Center for Youth Mental Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia

Correspondence:

Dr. Rasool Mohammadi

⁵ Social Determinants of Health Research Center, School of Public Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran

⁶Department of Biostatistics and Epidemiology, School of Public Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran

Email: rasool.mehr2002@gmail.com

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests:

The authors declare that there are no conflicts of interest.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions: BA. Conceived the study BA. collected all data. RM, and BA analyzed and interpreted the data. BA, EA and AB. drafted the manuscript. BA, MDG and MJF contributed to the revised paper and were responsible for all final editing. All authors commented on the drafts of the manuscript and approved the final copy of the paper for submission.

Acknowledgments:

Not applicable.

1 **Determinants of emergency department use and hospitalization among people who inject**
2 **drugs: A systematic review and meta-analysis**

3 **Abstract**

4 **Background:** The present study aimed to identify sociodemographic characteristics, risky
5 behaviors, type of drug use, and service use variables associated with emergency department (ED)
6 use and hospitalization among people who inject drugs (PWID).

7 **Methods:** Studies in English published from January 1, 1995 to December 15, 2021 were searched
8 for on *PubMed*, *Scopus*, *Cochrane*, and *Web of Science* to identify primary studies on ED use and
9 hospitalization among PWID.

10 **Results:** After a detailed assessment of 17,348 studies, a total of 19 studies met the eligibility
11 criteria for inclusion in the analysis. Greater risks of ED use and hospitalization among PWID
12 were associated with (i) history of homelessness, (ii) HIV-positive status, and (iii) injecting drugs
13 more than four times per day. Individuals were more likely to use the ED if they (i) had a history
14 of physical abuse, (ii) were using cocaine and methamphetamine, and (iii) had used primary care
15 services. Women and individuals having chronic physical illnesses were more likely to be
16 hospitalized.

17 **Conclusions:** The present study is the first to integrate determinants related to ED use and
18 hospitalization based on sociodemographic characteristics, risky behaviors, type of drug, and
19 service use determinants among PWID. To reduce ED use and hospitalization among PWID, the
20 paper also recommends various strategies could be implemented.

21

- 1 **Keywords:** emergency department use; hospitalization; people who inject drugs; psychoactive
- 2 substances; primary care services
- 3

FOR PEER REVIEW ONLY

1 **Introduction**

2 People who inject drugs (PWID) are more likely to frequently use hospital emergency
3 departments (EDs) and be hospitalized (i.e., receive acute care) than those who do not inject drugs
4 (Nambiar, Stoové, & Dietze, 2017; Palepu et al., 2001). A Canadian study reported 64% of PWID
5 had ED use in the previous 12 months, and 35% of them had at least two ED visits during that
6 period (Fairbairn et al., 2012). Moreover, hospitalization rates have been reported to range from
7 35% to 40% among PWID (Palepu et al., 2001; Takahashi et al., 2007). PWID are affected by
8 depressive and psychotic disorders (Michel et al., 2022; Reddon et al., 2018) and/or physical
9 diseases such as HIV infection or hepatitis C, which may result in greater ED use and/or
10 hospitalization (Kendall et al., 2017; Lloyd-Smith et al., 2010).

11 ED use and hospitalization are the most costly health services (Galarraga et al., 2016; Mejia
12 de Grubb et al., 2020). They are also key indicators of adverse outcomes (Armoon, Grenier, et al.,
13 2021; Fleury et al., 2019), and may be the sign of poor access or insufficient quality of outpatient
14 care (Sørup et al., 2013). PWD need harm reduction interventions, including access to needle and
15 syringe programs (Noroozi et al., 2018; Noroozi et al., 2019) and safe injecting facilities (Kerr et
16 al., 2007). However, PWID often do not take benefit of such services, and many of them do not
17 receive helpful support such as long-term primary care services (Chitwood et al., 2001).

18 To the best of the present authors' knowledge, no systematic review and meta-analysis has
19 previously investigated determinants of ED use and hospitalization among PWID. Identifying
20 determinants of ED use and hospitalization among PWID can help inform healthcare decision-
21 makers regarding unmet health needs for this vulnerable population, and help in the development
22 of strategies to reduce acute care use. Additionally, since drug use appears to be increasing in many
23 countries (Brunt et al., 2021; Seitz et al., 2019), comprehensive knowledge of acute care use of

1 PWID is essential to meet their needs and help in the consolidation of effective drug policy. The
2 present study aimed to identify sociodemographic characteristics, risky behaviors (such as HIV-
3 positive status, injecting drugs more than four times per day), type of drug use, and service use
4 variables associated with ED use and hospitalization among PWID.

5 **Methods**

6 ***Search strategy and study selection***

7 Two independent researchers individually reviewed the literature from January 1, 1995 to
8 December 15, 2021 using *PubMed*, *Scopus*, *Web of Science*, and *Cochrane* databases. A librarian
9 confirmed the search strategy, and it was modified for using in different databases including
10 Boolean operators (AND/OR) and initial keywords “(emergency medical services), (emergency
11 service, hospital), (hospitalization), (injection drug), (people who inject drugs), (substance abuse,
12 intravenous)”. References of the included studies were also searched by hand for further relevant
13 studies (see **Supplementary File 1**).

14 ***Inclusion and exclusion criteria***

15 All studies had to meet inclusion criteria based on “Population, exposures, comparison,
16 outcome, and study design” (PECOs) criteria. In “population” only PWID was included; for
17 “exposures”, associations with sociodemographic characteristics, risky behaviors, type of drug
18 use, and service use variables regarding PWID on ED use and hospitalization were assessed; the
19 “comparison” group was PWID not reporting ED use and hospitalization; the “outcomes” were
20 ED use and hospitalization among PWID; finally, the “study design” integrated cross-sectional,
21 cohort or case-control studies. For outcome, the previous six or twelve months of ED use or
22 hospitalization (yes or no) among PWID was considered. To be included in the present study, at

1 least two studies with the same acute care measure needed to be found, which is a minimal standard
2 of meta-analyses study inclusion (Ryan, 2016). Studies were excluded if they were (i) qualitative,
3 (ii) not written in English, (iii) did not include primary data, (iv) abstracts, books, theses, or
4 conference proceedings, systematic reviews, and meta-analyses. Studies with high heterogeneity
5 or outcome variations from the considered groups were also excluded.

6 ***Data extraction procedure***

7 Two of the authors (BA and AB) independently reviewed and evaluated the selected
8 papers, based on a standardized data collection checklist. The two researchers independently
9 selected the studies in a four-phase monitoring procedure. Initially, the duplicated titles/abstracts
10 (89% agreement) meeting the Newcastle-Ottawa Scale criteria (explained below), were removed.
11 Next, the papers' titles/abstracts were screened for full-text review based on the inclusion criteria
12 of the study (96% agreement). Any disagreements between the authors were resolved by a third
13 author (EA). Following this, the full texts of selected papers were reviewed. Finally, the required
14 data were extracted from the selected papers. Data extraction and management were performed in
15 *Microsoft Excel* software.

16 ***Quality assessment of the studies***

17 The Newcastle-Ottawa Scale (NOS); (Stang, 2010) was used to examine the quality of the
18 reviewed studies. There are three domains of selection, comparability, and exposure/outcome in
19 the NOS comprising 3, 1, and 1 items for cross-sectional studies and 4, 1, and 3 items for cohort
20 studies. The studies were also categorized as unsatisfactory, satisfactory, good, or very good. The
21 agreement levels of poor, slight, fair, moderate, substantial, and almost perfect were considered by
22 the values 0, 0.01–0.02, 0.021–0.04, 0.041–0.06, 0.061–0.08, and 0.081–1.00, respectively (Landis

1 et al., 1977). In total, seven studies were rated as high quality, eight studies were rated as good
2 quality, and four were rated as satisfactory quality. (**Supplementary File 2**).

3 ***Data synthesis and statistical analysis***

4 Systematic review and meta-analysis were performed by generating pooled odds ratios
5 (ORs) and 95% confidence intervals (CIs) for determining variables associated with ED use and
6 hospitalization among PWID. The OR was computed by a 2x2 table, and an OR of <1
7 demonstrated a negative correlation between ED use and hospitalization and the target
8 characteristic. An OR of >1 (i.e., the statistical threshold for examining the correlation between
9 ED use and hospitalization and expositive variables) reflects positive correlation between ED use
10 and hospitalization and independent variables. To evaluate the correlation between studies, the Q
11 test at $p < 0.05$ and I^2 statistics (with a cutoff point of $\geq 50\%$) were used as the most optimal choices.
12 A 95%CI was considered for I^2 . However, the negative scores were considered at zero. To achieve
13 the pooled estimation, the random-effects model was used, considering different sampling methods
14 implemented in the studies. Egger's publication bias test was used to identify any existing
15 publication bias (Egger et al., 1997). Subsequently, the obtained data were illustrated in forest
16 plots. The *R version 3.5.1* with the "*meta*" package was applied to perform the meta-analysis of
17 the collected data (Viechtbauer, 2010).

18 **Results**

19 ***Study characteristics***

20 After a detailed assessment of 17,348 studies, a total of 19 studies were included in the
21 present study for inclusion in the analysis (Binswanger et al., 2008; Fairbairn et al., 2012; Hope et
22 al., 2015; Islam et al., 2013; Kerr et al., 2005; Knowlton et al., 2001; Lloyd-Smith et al., 2012;
23 Lloyd-Smith et al., 2010; Marshall et al., 2012; McDonald et al., 2011; Nambiar et al., 2018;

1 Nambiar, Stoové, & Dietze, 2017; Nambiar, Stoové, Hickman, et al., 2017; Olubamwo et al., 2018;
2 Palepu et al., 2003; Palepu et al., 1999; Palepu et al., 2001; Stein et al., 2003; Takahashi et al.,
3 2007) (**Figure 1**). A total of 275 studies were excluded because they did not use a quantitative
4 methodology and/or did not consider parametric measurements such as coefficients and odd ratios
5 of relative to ED use and/or hospitalization (37%), 127 studies did not consider ED use or
6 hospitalization for their outcome variables, or did not have a dichotomous variable (i.e., acute care
7 use: yes, or no) (17%). Finally, 333 studies did not meet the qualifications based on the minimum
8 quality appraisal (45%).

9 **Figure 1 near here**

10 *Study characteristics*

11 Canada had the highest number of studies (n=8, comprising 6,212 participants) followed
12 by the United States (n=4, comprising 1,051 participants) and Australia (n=4, comprising 7,201
13 participants). All studies were conducted within high-income countries. Mean study size at
14 baseline was 3,142 PWID, with 147 being the lowest sample size (Takahashi et al., 2007), and
15 41,062 being the largest sample size (McDonald et al., 2011), respectively. Response rates varied
16 between studies from 74% to 100%, respectively. PWID were more likely to be male in the studies
17 (67.83%), varying from 60% to 75%, and on average were 34.82 years old. Almost all of the
18 studies were cohort (89%), and 58% of studies were published between 2010 and 2021. Three
19 studies assessed both ED use and hospitalization as the outcomes, using administrative databases
20 or self-reported surveys. Nine studies assessed ED use only, and seven studies assessed
21 hospitalization only as the outcome, using administrative databases, self-report surveys or both
22 administrative databases and surveys. Main types of drug use disorders reported in studies were
23 polydrug use (n=6 studies), heroin and cocaine use (n=5 studies), and methamphetamine use (n=2

1 studies). This suggests that their main drug of choice is not necessarily the one that they had
2 injected. Six studies did not report specific types of drug use disorders relating to PWID globally.
3 Among the 19 studies included in the meta-analysis, 10 reported sociodemographic characteristics,
4 14 reported risky behaviors, seven reported type of drug use, and eight reported service use
5 variables (**Table 1**).

6
7 **Table 1 near here**

8 ***Pooled prevalence rate of ED use and hospitalization among PWID***

9 The pooled prevalence rate of ED use and hospitalization among PWID were 49% (95%
10 CI, 40%-59%) (**Figure 2**) and 27% (95% CI, 16%-38%) (**Figure 3**) respectively.

11 **Figures 2 and 3 near here**

12 ***Sociodemographic characteristics, risky behaviors, type of drug use and service use variables***
13 ***associated with ED use and hospitalization among PWID***

14 In four ED use studies (Fairbairn et al., 2012; Palepu et al., 2003; Palepu et al., 1999; Palepu
15 et al., 2001) and three hospitalization studies (Olubamwo et al., 2018; Palepu et al., 1999;
16 Takahashi et al., 2007), those who had a history of homelessness were reported to use ED or to be
17 hospitalized 1.52 and 1.63 times more than non-homeless individuals, respectively (OR=1.52,
18 95%CI=1.29-1.78) (OR=1.63, 95%CI=1.34-1.97). In two studies (Fairbairn et al., 2012; Kerr et
19 al., 2005), those who had a history of physical abuse were 1.38 times more likely to report ED use
20 (OR=1.38, 95%CI=1.12-1.69). In three studies (McDonald et al., 2011; Palepu et al., 1999; Palepu
21 et al., 2001), PWID who were women were 1.54 times more likely to have been hospitalized
22 (OR=1.54, 95%CI=1.34-1.78). In five ED use studies (Kerr et al., 2005; Knowlton et al., 2001;

1 Lloyd-Smith et al., 2012; Palepu et al., 1999; Palepu et al., 2001) and three hospitalization studies
2 (Lloyd-Smith et al., 2010; Palepu et al., 1999; Palepu et al., 2001), those who had HIV infection
3 were reported to use ED or to be hospitalized 1.66 and 2.37 times more than who did not have HIV
4 infection, respectively (OR = 1.66, 95%CI = 1.42-1.95) (OR = 2.37, 95%CI = 1.07-5.26). In two
5 ED use studies (Palepu et al., 2001; Stein et al., 2003) and two hospitalization studies (Olubamwo
6 et al., 2018; Stein et al., 2003), those who injected drugs more than four times per day were
7 reported to use EDs or to be hospitalized 1.29 and 1.39 times more than who did not respectively
8 (OR=1.29, 95%CI=1.05-1.57) (OR=1.39, 95%CI=1.15-1.69). In two studies (Binswanger et al.,
9 2008; Stein et al., 2003), those who had chronic physical illnesses were 1.55 times more likely to
10 be hospitalized compared to those who did not (OR = 1.55, 95%CI = 1.23, 1.96). In three ED use
11 studies (Kerr et al., 2005; Marshall et al., 2012; Nambiar, Stoové, & Dietze, 2017) and three studies
12 related to ED use (Palepu et al., 1999; Palepu et al., 2001; Stein et al., 2003), PWID who used
13 methamphetamine were 2.10 times more likely to have ED use (OR=2.10, 95%CI=1.39-3.16), and
14 PWID who used cocaine were 1.48 times more likely to have ED use, respectively (OR=1.48,
15 95%CI=1.23-1.79). Finally, in four ED use studies (Fairbairn et al., 2012; Kerr et al., 2005;
16 Nambiar, Stoové, Hickman, et al., 2017; Palepu et al., 1999), those who reported using primary
17 care services were 1.87 times more likely to have ED use than those who did not (OR=1.87,
18 95%CI=1.49-2.35) (**Figures 4 and 5**).

19 **Figures 4 and 5 near here**

20 ***Publication bias***

21 To identify the probable publication bias, Egger's test (Egger et al., 1997) and the graph
22 were performed. According to Eggers test, a significant publication bias among studies was noted

1 (coefficient = 3.43, $p < 0.001$). Therefore, metatrim analysis was performed in order to remove the
2 effect of publication bias on the pooled OR. The meta-trim analysis showed that the pooled OR
3 was 0.15 (95%CI: 0.11–0.19) in the random effect model.

4 **Discussion**

5 Findings from the meta-analysis indicated that among people who inject drugs (PWID),
6 the pooled rate for ED use was 49% and the pooled rate for hospitalization was 27%. No pooled
7 prevalence for acute care has previously been reported in relation to PWID. Some of the reasons
8 for this may be because PWID have high rates of injection frequency that may increase the risk of
9 HIV infection, soft-tissue infections, and pneumonia, as well as being engaged with a risky
10 behavior that has a high association with various suicidal behaviors (e.g., suicide ideations, suicide
11 attempts (Armoon, Fleury, et al., 2022; Armoon, Higgs, et al., 2021; Moradi-Joo et al., 2019;
12 Rezaei et al., 2020), all of which would increase the chances of needing acute care. PWID with
13 history of homelessness and HIV-positive status were the most at risk of being both ED users and
14 being hospitalized. Using methamphetamine and cocaine as well as using primary care services
15 also increased the risk of ED use only, while being women who injected drugs increased the risk
16 of hospitalization only.

17 Having a history of homelessness was the only sociodemographic determinant associated
18 with both ED use and hospitalization. More specifically, homelessness elevated the risk of ED use
19 and hospitalization by 1.52 and 1.63, respectively. Studies have indicated that 40% (Palepu et al.,
20 2003) to 69% (Fairbairn et al., 2012) of PWID who are homelessness have used EDs, and that 24%
21 (Takahashi et al., 2007) to 66% (Palepu et al., 1999) have been hospitalized. The association
22 between homelessness and acute care services was found previously in studies conducted with
23 PWID (McGeary et al., 2000; Nambiar et al., 2018). According to the literature, individuals having

1 a history of homelessness are more likely to have severe infections (Takahashi et al., 2007), acute
2 illnesses (Rickards et al., 2010), mental disorders (Latimer et al., 2017), substance-related
3 disorders (Magwood et al., 2020), injuries (Mackelprang et al., 2014), and suicidal behaviors
4 (Gentil et al., 2021).

5 The association between ED use and a history of physical abuse has also been found in
6 previously studies (Kerr et al., 2003; Tyndall et al., 2002). According to the literature, individuals
7 who have a history of physical abuse, have higher risks of injection drug initiation, which may
8 lead to ED use (Prangnell et al., 2020). Previous studies have reported that between 21%
9 (McDonald et al., 2011) and 43% (Palepu et al., 2001) of women who inject drugs are likely to be
10 hospitalized. According to the literature (Shapiro et al., 1999; Solomon et al., 1998), compared to
11 men, women are more likely to be hospitalized and to show adverse outcomes associated with
12 substance-related disorders (Beaudoin et al., 2015; John et al., 2017; Trillo et al., 2012), which
13 may also explain their higher risk of hospitalization in the present study.

14 The risk of ED use and hospitalization was especially elevated among PWID who have
15 HIV positive status, being 1.66 and 2.37 higher, respectively. Studies have indicated that 13%
16 (Knowlton et al., 2001) to 54% (Palepu et al., 2001) of those with HIV positive status used EDs,
17 and that 28% (Palepu et al., 1999) to 39% (Palepu et al., 2001) of them are hospitalized. Previous
18 studies have found that drug injection increases the risk of infection by HIV (Ball et al., 2019;
19 Mathers et al., 2008), which might increase the risk of ED use or hospitalization (Archibald et al.,
20 1998).

21 Studies have reported that 32% (Stein et al., 2003) to 35% (Palepu et al., 2001) of PWID
22 who inject drugs more than four times a day have used EDs, and 32% (Stein et al., 2003) to 47%
23 (Olubamwo et al., 2018) among this group have been hospitalized. Higher injection frequency

1 increases the risk of overdose (Armoon, Bayani, et al., 2022), which can lead to ED use and
2 hospitalization (Stein et al., 2003). Unsurprisingly, chronic physical illnesses increased the
3 expected odds of hospitalization (by a factor of 1.55). A previous study reported that 58% of PWID
4 with chronic physical illnesses had been hospitalized (Binswanger et al., 2008). PWID had an
5 elevated risk of contributing to or causing concurrent medical conditions (e.g., diabetes, high blood
6 pressure, cardiovascular diseases and infective endocarditis) (Binswanger et al., 2008; Rudasill et
7 al., 2019; Stein et al., 2003), which helps explain hospitalization.

8 The main type of drugs associated with ED use was methamphetamine use. PWID who
9 used methamphetamine were 2.10 more likely to use EDs. Studies have reported 11% (Nambiar,
10 Stoové, & Dietze, 2017) to 30% (Marshall et al., 2012) of PWID who use methamphetamine
11 reported ED use. The association between ED use and methamphetamine has been reported in
12 previous studies (Hendrickson et al., 2008; Marshall et al., 2012), and can be explained by the
13 serious adverse consequences of methamphetamine on health and psychological functioning,
14 which justify ED use (Sommers et al., 2006). ED use might also be explained by the lack of access
15 to other outpatient forms of treatment modalities, or the absence of suitable outpatient treatment
16 programs for PWID who use methamphetamine (Hendrickson et al., 2008). PWID who use
17 cocaine have been reported to have 1.48 times elevated risk of ED use. Studies have also reported
18 that 20% (Palepu et al., 1999) to 47% (Palepu et al., 2001) of those who use cocaine are likely to
19 report ED use. Spanish studies have previously reported a significant relationship between the
20 odds of ED use and cocaine use (Miró et al., 2019; Sanvisens et al., 2021), with one of them
21 reporting a 18% re-admission rate among ED users due to cocaine use (Sanvisens et al., 2021).
22 This confirms an association between cocaine use and severe complications (Butler et al., 2017;
23 Degenhardt et al., 2011). Cocaine users have also been reported as having a higher risk of non-

1 fatal and fatal overdose compared to those who do not use cocaine (Armoon, Mohammadi, et al.,
2 2021; Armoon, SoleimanvandiAzar, et al., 2022). Moreover, cocaine use in recreational context
3 may lead to accidents or aggressive behaviors that increase risk of ED use (Fulde et al., 2015).

4 Primary care services were the only service use determinant of ED use. PWID using
5 primary care services had elevated risk of ED use by 1.87 compared to those who did not. Studies
6 have reported that between 57% (Nambiar, Stoové, & Dietze, 2017) and 85% (Palepu et al., 1999)
7 of primary care service users are ED users. This association may be explained by the frequent
8 medical problems reported among many PWID, usually resulting in them using primary care
9 services first. However, many of their acute problems (e.g., overdose) may not be adequately
10 managed in primary care, which consequently leads to referral to EDs or hospitalization. Some
11 risky behaviors among PWID, such as non-fatal overdose and needle sharing, might also require
12 primary healthcare interventions after ED use (Kerr et al., 2005).

13 ***Methodological considerations related to results***

14 In the present systematic review and meta-analysis, a number of methodological concerns
15 are worth noting. First, different instruments were used in the studies to assess PWID such as the
16 *International Classification of Diseases* (ninth and tenth revision) in administrative database
17 studies, and the Addiction Severity Index in survey studies. Therefore, it may be difficult to
18 directly compare different types of PWID. Second, variables not reported in more than two studies
19 were not included in the meta-analysis, such as employment status, non-fatal overdose, duration
20 of injection, cannabis use disorders, and use of mental health services. Third, the present study
21 integrated findings from a limited number of selected papers. Considering sociodemographic
22 characteristics, only six studies examined a history of homelessness being associated with ED use
23 and/or hospitalization, only three studies examined being female being associated with ED use,

1 and only two studies examined a history of physical abuse being associated with ED use.
2 Therefore, interpretation of the results should be exercised with caution. Considering risky
3 behaviors associated with ED use or hospitalization, only six studies examined HIV positive status
4 being associated with ED use and/or hospitalization, only four studies examined injecting drugs
5 more than four times per day being associated with ED use and/or hospitalization, and only two
6 studies examined chronic physical illnesses being associated with hospitalization. There was high
7 heterogeneity among HIV positive status. Therefore, the associations may not be strong. Regarding
8 risky behaviors, the number of studies were especially low, again raising the need to be cautious
9 when interpreting the study's findings.

10 Considering types of drug use, four studies reported cocaine use disorder, and three studies
11 reported methamphetamine use disorder being associated with ED use, in which high
12 heterogeneity existed among cocaine use disorder. Therefore, this heterogeneity needs to be taken
13 into account when considering the association between use of psychoactive substances and ED
14 use.

15 Considering service use variables, only four studies were included associated with ED use.
16 Therefore, further studies are needed to confirm the findings here. Finally, in some cases, there
17 was high heterogeneity between studies. This meant several subgroup analyses were applied to
18 decrease the effect of heterogeneity. However, not all sources of heterogeneity could be
19 considered, because with more subgroup analyses, the number of studies in each subgroup
20 decreases. In consequence, a larger number of studies are needed to establish more reliable results.

21 **Conclusions**

1 The present study is the first to integrate determinants related to ED use and hospitalization
2 based on sociodemographic characteristics, risky behaviors, type of drug, and service use
3 determinants among PWID. The finding showed that the most important predictors of ED use or
4 hospitalization were being HIV positives status, methamphetamine users, and having an history of
5 homelessness. A novel finding was that the use of primary care services significantly increased
6 the risk of ED use. Therefore, better collaboration between acute and primary care services is
7 recommended for PWID having HIV positive status or chronic physical illnesses in view to reduce
8 their frequency of ED use. ED liaison nurses in acute care should facilitate referral to addiction
9 treatment centers, especially for patients using cocaine and methamphetamine. ED use and
10 hospitalization of PWID might also be reduced by developing outpatient programs with harm
11 reduction strategies (e.g., safer injecting advice and greater accessibility to sterile needles). Finally,
12 outreach strategies are recommended for PWID having an history of homelessness for improving
13 their overall accessibility to outpatient health care services.

14 **Abbreviations**

15 CI: Confidence intervals

16 ED: Emergency department

17 NOS: Newcastle-Ottawa Scale

18 OR: Odds ratio

19 PICO: Population, intervention, comparison, outcome, study design

20 PRISMA: Protocols of systematic reviews and meta-analyses

21 PWID: People who inject drugs

1 **References**

2

3

4 Archibald, C. P., Ofner, M., Strathdee, S. A., Patrick, D. M., Sutherland, D., Rekart, M. L., Schechter, M.
5 T., & O'Shaughnessy, M. V. (1998). Factors associated with frequent needle exchange program
6 attendance in injection drug users in Vancouver, Canada. *Journal of Acquired Immune Deficiency*
7 *Syndromes*, 17(2), 160-166. doi: 10.1097/00042560-199802010-00010

8

9 Armoon, B., Bayani, A., Griffiths, M. D., Bayat, A.-H., Mohammadi, R., Fattah Moghaddam, L., &
10 Ahounbar, E. (2022). Prevalence and high-risk behaviors associated with non-fatal overdose
11 among people who use illicit opioids: A systematic review and meta-analysis. *Journal of*
12 *Substance Use*, 27(6), 569-584. doi: 10.1080/14659891.2021.1978112

13

14 Armoon, B., Fleury, M.-J., Bayani, A., Mohammadi, R., Ahounbar, E., & Griffiths, M. D. (2022).
15 Suicidal behaviors among intravenous drug users: A meta-analysis. *Journal of Substance Use*, 1-
16 11. doi: 10.1080/14659891.2022.2120435

17

18 Armoon, B., Grenier, G., Cao, Z., Huỳnh, C., & Fleury, M.-J. (2021). Frequencies of emergency
19 department use and hospitalization comparing patients with different types of substance or
20 polysubstance-related disorders. *Substance Abuse Treatment, Prevention, and Policy*, 16(1), 89.
21 doi: 10.1186/s13011-021-00421-7

22

23 Armoon, B., Higgs, P., & Mohammadi, R. (2021). Mental health status, health service utilization, drug
24 use behaviors associated with non-fatal overdose among people who use illicit drugs: A meta-
25 analysis. *Journal of Substance Use*, 1-12. doi: 10.1080/14659891.2021.2019331

26

- 1 Armoon, B., Mohammadi, R., Fattah Moghaddam, L., & Gonabadi-Nezhad, L. (2021). Type of drug use
2 and risky determinants associated with fatal overdose among people who use drugs: A meta-
3 analysis. *Journal of Substance Use*, 1-11. doi: 10.1080/14659891.2021.2019329
- 4
- 5 Armoon, B., SoleimanvandiAzar, N., Rostami, M., Higgs, P., Bayani, A., Bayat, A.-H., Mohammadi, R.,
6 Ahounbar, E., & Fattah Moghaddam, L. (2022). Drug type and risk behaviors associated with
7 non-fatal overdose among people who use drugs: A systematic review and meta-analysis. *Journal*
8 *of Addictive Diseases*, 40(1), 114-125. doi: 10.1080/10550887.2021.1950262
- 9
- 10 Ball, L. J., Puka, K., Speechley, M., Wong, R., Hallam, B., Wiener, J. C., Koivu, S., & Silverman, M. S.
11 (2019). Sharing of injection drug preparation equipment is associated with HIV infection: A
12 cross-sectional study. *Journal of Acquired Immune Deficiency Syndromes*, 81(4), e99-e103. doi:
13 10.1097/qai.0000000000002062
- 14
- 15 Beaudoin, F. L., Baird, J., Liu, T., & Merchant, R. C. (2015). Sex differences in substance use among
16 adult emergency department patients: Prevalence, severity, and need for intervention. *Academic*
17 *Emergency Medicine*, 22(11), 1307-1315. doi: 10.1111/acem.12810
- 18
- 19 Binswanger, I. A., Takahashi, T. A., Bradley, K., Dellit, T. H., Benton, K. L., & Merrill, J. O. (2008).
20 Drug users seeking emergency care for soft tissue infection at high risk for subsequent
21 hospitalization and death. *Journal of Studies on Alcohol and Drugs*, 69(6), 924-932. doi:
22 10.15288/jsad.2008.69.924
- 23
- 24 Brunt, T. M., Lefrançois, E., Gunnar, T., Arponen, A., Seyler, T., Goudriaan, A. E., McAuley, A.,
25 McKeown, D. A., Detrez, V., Csorba, J., Deimel, D., Auwärter, V., Kempf, J., Karolak, S., &
26 Nefau, T. (2021). Substances detected in used syringes of injecting drug users across 7 cities in
27 Europe in 2017 and 2018: The European Syringe Collection and Analysis Project Enterprise

1 (ESCAPE). *International Journal of Drug Policy*, 95, 103130. doi:
2 <https://doi.org/10.1016/j.drugpo.2021.103130>

3

4 Butler, A. J., Rehm, J., & Fischer, B. (2017). Health outcomes associated with crack-cocaine use:
5 Systematic review and meta-analyses. *Drug and Alcohol Dependence*, 180, 401-416. doi:
6 10.1016/j.drugalcdep.2017.08.036

7

8 Chitwood, D. D., Sanchez, J., Comerford, M., & McCoy, C. B. (2001). Primary preventive health care
9 among injection drug users, other sustained drug users, and non-users. *Substance Use & Misuse*,
10 36(6-7), 807-823. doi: 10.1081/ja-100104092

11

12 Degenhardt, L., Singleton, J., Calabria, B., McLaren, J., Kerr, T., Mehta, S., Kirk, G., & Hall, W. D.
13 (2011). Mortality among cocaine users: A systematic review of cohort studies. *Drug and Alcohol*
14 *Dependence*, 113(2-3), 88-95. doi: 10.1016/j.drugalcdep.2010.07.026

15

16 Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple,
17 graphical test. *BMJ*, 315(7109), 629-634. doi: 10.1136/bmj.315.7109.629

18

19 Fairbairn, N., Milloy, M.-J., Zhang, R., Lai, C., Grafstein, E., Kerr, T., & Wood, E. (2012). Emergency
20 department utilization among a cohort of HIV-positive injecting drug users in a Canadian setting.
21 *Journal of Emergency Medicine*, 43(2), 236-243. doi: 10.1016/j.jemermed.2011.05.020

22

23 Fleury, M.-J., Fortin, M., Rochette, L., Grenier, G., Huynh, C., Pelletier, É., & Vasiliadis, H.-M. (2019).
24 Assessing quality indicators related to mental health emergency room utilization. *BMC*
25 *Emergency Medicine*, 19(1), 8. doi: 10.1186/s12873-019-0223-8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Fulde, G. W. O., & Forster, S. L. (2015). The impact of amphetamine-type stimulants on emergency services. *Current Opinion in Psychiatry*, 28(4), 275-279. doi: 10.1097/ycp.0000000000000171

Galarraga, J. E., & Pines, J. M. (2016). Costs of ED episodes of care in the United States. *American Journal of Emergency Medicine*, 34(3), 357-365. doi: 10.1016/j.ajem.2015.06.001

Gentil, L., Grenier, G., & Fleury, M.-J. (2021). Determinants of suicidal ideation and suicide attempt among former and currently homeless individuals. *Social Psychiatry and Psychiatric Epidemiology*, 56(5), 747-757. doi: 10.1007/s00127-020-01952-3

Hendrickson, R. G., Cloutier, R., & McConnell, K. J. (2008). Methamphetamine-related emergency department utilization and cost. *Academic Emergency Medicine*, 15(1), 23-31. doi: 10.1111/j.1553-2712.2007.00006.x

Hope, V., Ncube, F., Parry, J., & Hickman, M. (2015). Healthcare seeking and hospital admissions by people who inject drugs in response to symptoms of injection site infections or injuries in three urban areas of England. *Epidemiology & Infection*, 143(1), 120-131. doi: 10.1017/S0950268814000284

Islam, M. M., Topp, L., Iversen, J., Day, C., Conigrave, K. M., & Maher, L. (2013). Healthcare utilisation and disclosure of injecting drug use among clients of Australia's needle and syringe programs. *Australian and New Zealand Journal of Public Health*, 37(2), 148-154. doi: 10.1111/1753-6405.12032

1 John, W. S., & Wu, L. T. (2017). Problem alcohol use and healthcare utilization among persons with
2 cannabis use disorder in the United States. *Drug and Alcohol Dependence*, 178, 477-484. doi:
3 10.1016/j.drugalcdep.2017.05.035

4

5 Kendall, C. E., Boucher, L. M., Mark, A. E., Martin, A., Marshall, Z., Boyd, R., Oickle, P., Diliso, N.,
6 Pineau, D., & Renaud, B. (2017). A cohort study examining emergency department visits and
7 hospital admissions among people who use drugs in Ottawa, Canada. *Harm Reduction Journal*,
8 14(1), 16. doi: 10.1186/s12954-017-0143-4

9

10 Kerr, T., Kimber, J., DeBeck, K., & Wood, E. (2007). The role of safer injection facilities in the response
11 to HIV/AIDS among injection drug users. *Current HIV/AIDS Reports*, 4(4), 158-164. doi:
12 10.1007/s11904-007-0023-8

13

14 Kerr, T., Wood, E., Grafstein, E., Ishida, T., Shannon, K., Lai, C., Montaner, J., & Tyndall, M. (2005).
15 High rates of primary care and emergency department use among injection drug users in
16 Vancouver. *Journal of Public Health*, 27(1), 62-66. doi: 10.1093/pubmed/fdh189

17

18 Kerr, T., Wood, E., Small, D., Palepu, A., & Tyndall, M. W. (2003). Potential use of safer injecting
19 facilities among injection drug users in Vancouver's Downtown Eastside. *Canadian Medical*
20 *Association Journal*, 169(8), 759-763.

21

22 Knowlton, A. R., Hoover, D. R., Chung, S.-e., Celentano, D. D., Vlahov, D., & Latkin, C. A. (2001).
23 Access to medical care and service utilization among injection drug users with HIV/AIDS. *Drug*
24 *and Alcohol Dependence*, 64(1), 55-62. doi: 10.1016/s0376-8716(00)00228-3

25

- 1 Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data.
2 *Biometrics*, 33(1), 159-174.
- 3
- 4 Latimer, E. A., Rabouin, D., Cao, Z., Ly, A., Powell, G., Aubry, T., Distasio, J., Hwang, S. W., Somers, J.
5 M., & Stergiopoulos, V. (2017). Costs of services for homeless people with mental illness in 5
6 Canadian cities: A large prospective follow-up study. *Canadian Medical Association Journal*
7 *Open*, 5(3), E576-E585. doi: 10.9778/cmajo.20170018
- 8
- 9 Lloyd-Smith, E., Tyndall, M., Zhang, R., Grafstein, E., Sheps, S., Wood, E., Montaner, J., & Kerr, T.
10 (2012). Determinants of cutaneous injection-related infections among injection drug users at an
11 emergency department. *Open Infectious Diseases Journal*, 6, 80176398. doi:
12 10.2174/1874279301206010005
- 13
- 14 Lloyd-Smith, E., Wood, E., Zhang, R., Tyndall, M. W., Sheps, S., Montaner, J. S., & Kerr, T. (2010).
15 Determinants of hospitalization for a cutaneous injection-related infection among injection drug
16 users: A cohort study. *BMC Public Health*, 10(1), 1-7. doi: 10.1186/1471-2458-10-327
- 17
- 18 Mackelprang, J. L., Graves, J. M., & Rivara, F. P. (2014). Homeless in America: injuries treated in US
19 emergency departments, 2007-2011. *International Journal of Injury Control and Safety*
20 *Promotion*, 21(3), 289-297. doi: 10.1080/17457300.2013.825631
- 21
- 22 Magwood, O., Salvalaggio, G., Beder, M., Kendall, C., Kpade, V., Daghmach, W., Habonimana, G.,
23 Marshall, Z., Snyder, E., O'Shea, T., Lennox, R., Hsu, H., Tugwell, P., & Pottie, K. (2020). The
24 effectiveness of substance use interventions for homeless and vulnerably housed persons: A
25 systematic review of systematic reviews on supervised consumption facilities, managed alcohol
26 programs, and pharmacological agents for opioid use disorder. *PloS One*, 15(1), e0227298. doi:
27 10.1371/journal.pone.0227298

1

2 Marshall, B., Grafstein, E., Buxton, J., Qi, J., Wood, E., Shoveller, J., & Kerr, T. (2012). Frequent
3 methamphetamine injection predicts emergency department utilization among street-involved
4 youth. *Public Health, 126*(1), 47-53. doi: 10.1016/j.puhe.2011.09.011

5

6 Mathers, B. M., Degenhardt, L., Phillips, B., Wiessing, L., Hickman, M., Strathdee, S. A., Wodak, A.,
7 Panda, S., Tyndall, M., Toufik, A., & Mattick, R. P. (2008). Global epidemiology of injecting
8 drug use and HIV among people who inject drugs: A systematic review. *Lancet, 372*(9651),
9 1733-1745. doi: 10.1016/s0140-6736(08)61311-2

10

11 McDonald, S. A., Hutchinson, S. J., Bird, S. M., Robertson, C., Mills, P. R., Dillon, J. F., & Goldberg, D.
12 J. (2011). Hospitalisation for an alcohol-related cause among injecting drug users in Scotland:
13 Increased risk following diagnosis with hepatitis C infection. *International Journal of Drug*
14 *Policy, 22*(1), 63-69. doi: 10.1016/j.drugpo.2010.04.003

15

16 McGeary, K. A., & French, M. T. (2000). Illicit drug use and emergency room utilization. *Health*
17 *Services Research, 35*(1 Pt 1), 153-169. doi: <https://pubmed.ncbi.nlm.nih.gov/10778828/>

18

19 Mejia de Grubb, M. C., Salemi, J. L., Gonzalez, S. J., Chima, C. C., Kowalchuk, A. A., & Zoorob, R. J.
20 (2020). Opioid, cocaine, and amphetamine use disorders are associated with higher 30-day
21 inpatient readmission rates in the United States. *Substance Abuse, 41*(3), 365-374. doi:
22 10.1080/08897077.2019.1635964

23

24 Michel, L., Le, S. M., Thi, G. H., Trouiller, P., Thi, H. D., Thi Hai, O. K., Minh, K. P., Vallo, R., Rapoud,
25 D., Quillet, C., Nguyen, T. L., Nguyen, Q. D., NhamThi, T. T., Feelemyer, J., Hai, V. V., Moles,
26 J.-P., Doan, H. Q., Laureillard, D., Des Jarlais, D. C., & Nagot, N. (2022). Assessment of a
27 psychiatric intervention at community level for people who inject drugs in a low-middle income

1 country: the DRIVE-Mind cohort study in Hai Phong, Viet Nam. *Lancet Regional Health –*
2 *Western Pacific*, 18, 100337. doi: 10.1016/j.lanwpc.2021.100337

3

4 Miró, Ò., Dargan, P. I., Wood, D. M., Dines, A. M., Yates, C., Heyerdahl, F., Hovda, K. E., Giraudon, I.,
5 Group, E.-D. P. R., & Galicia, M. (2019). Epidemiology, clinical features and management of
6 patients presenting to European emergency departments with acute cocaine toxicity: Comparison
7 between powder cocaine and crack cocaine cases. *Clinical Toxicology*, 57(8), 718-726. doi:
8 10.1080/15563650.2019.1613549

9

10 Moradi-Joo, M., Ghiasvand, H., Noroozi, M., Armoon, B., Noroozi, A., Karimy, M., Rostami, A.,
11 Mirzaee, M. S., & Hemmat, M. (2019). Prevalence of skin and soft tissue infections and its
12 related high-risk behaviors among people who inject drugs: A systematic review and meta-
13 analysis. *Journal of Substance Use*, 24(4), 350-360. doi: 10.1080/14659891.2019.1572805

14

15 Nambiar, D., Spelman, T., Stoove, M., & Dietze, P. (2018). Are people who inject drugs frequent users of
16 emergency department services? A cohort study (2008–2013). *Substance Use & Misuse*, 53(3),
17 457-465. doi: 10.1080/10826084.2017.1341921

18

19 Nambiar, D., Stoové, M., & Dietze, P. (2017). Frequent emergency department presentations among
20 people who inject drugs: A record linkage study. *International Journal of Drug Policy*, 44, 115-
21 120. doi: 10.1016/j.drugpo.2017.03.010

22

23 Nambiar, D., Stoové, M., Hickman, M., & Dietze, P. (2017). A prospective cohort study of hospital
24 separations among people who inject drugs in Australia: 2008–2013. *BMJ Open*, 7(8), e014854.
25 doi: 10.1136/bmjopen-2016-014854

26

- 1 Noroozi, M., Marshall, B. D., Noroozi, A., Armoon, B., Sharifi, H., Farhoudian, A., Ghiasvand, H.,
2 Vameghi, M., Rezaei, O., & Sayadnasiri, M. (2018). Do needle and syringe programs reduce
3 risky behaviours among people who inject drugs in Kermanshah City, Iran? A coarsened exact
4 matching approach. *Drug and Alcohol Review*, 37(Suppl 1), S303-S308. doi: 10.1111/dar.12646
- 5
- 6 Noroozi, M., Noroozi, A., Sharifi, H., Harouni, G. G., Marshall, B. D., Ghisvand, H., Qorbani, M., &
7 Armoon, B. (2019). Needle and syringe programs and HIV-related risk behaviors among men
8 who inject drugs: A multilevel analysis of two cities in Iran. *International Journal of Behavioral*
9 *Medicine*, 26(1), 50-58. doi: 10.1007/s12529-018-9758-4
- 10
- 11 Olubamwo, O. O., Onyeka, I. N., Aregbesola, A., Ronkainen, K., Tiihonen, J., Föhr, J., & Kauhanen, J.
12 (2018). Determinants of hospitalizations for pneumonia among Finnish drug users. *SAGE Open*
13 *Medicine*, 6, 2050312118784311. doi: 10.1177/2050312118784311
- 14
- 15 Palepu, A., Horton, N. J., Tibbetts, N., Dukes, K., Meli, S., & Samet, J. H. (2003). Substance abuse
16 treatment and emergency department utilization among a cohort of HIV-infected persons with
17 alcohol problems. *Journal of Substance Abuse Treatment*, 25(1), 37-42. doi: 10.1016/s0740-
18 5472(03)00064-3
- 19
- 20 Palepu, A., Strathdee, S. A., Hogg, R. S., Anis, A. H., Rae, S., Cornelisse, P. G., Patrick, D. M.,
21 O'Shaughnessy, M. V., & Schechter, M. T. (1999). The social determinants of emergency
22 department and hospital use by injection drug users in Canada. *Journal of Urban Health*, 76(4),
23 409-418. doi: 10.1007/BF02351499
- 24
- 25 Palepu, A., Tyndall, M. W., Leon, H., Muller, J., O'Shaughnessy, M. V., Schechter, M. T., & Anis, A. H.
26 (2001). Hospital utilization and costs in a cohort of injection drug users. *Canadian Medical*
27 *Association Journal*, 165(4), 415-420.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Prangnell, A., Imtiaz, S., Karamouzian, M., & Hayashi, K. (2020). Childhood abuse as a risk factor for injection drug use: A systematic review of observational studies. *Drug and Alcohol Review*, 39(1), 71-82. doi: 10.1111/dar.13001

Reddon, H., Pettes, T., Wood, E., Nosova, E., Milloy, M.-J., Kerr, T., & Hayashi, K. (2018). Incidence and predictors of mental health disorder diagnoses among people who inject drugs in a Canadian setting. *Drug and Alcohol Review*, 37 Suppl 1(Suppl 1), S285-S293. doi: 10.1111/dar.12631

Rezaei, O., Ghiasvand, H., Higgs, P., Noroozi, A., Noroozi, M., Rezaei, F., Armoon, B., & Bayani, A. (2020). Factors associated with injecting-related risk behaviors among people who inject drugs: A systematic review and meta-analysis study. *Journal of Addictive Diseases*, 38(4), 420-437. doi: 10.1080/10550887.2020.1781346

Rickards, L. D., McGraw, S. A., Araki, L., Casey, R. J., High, C. W., Hombs, M. E., & Raysor, R. S. (2010). Collaborative initiative to help end chronic homelessness: Introduction. *Journal of Behavioral Health Services & Research*, 37(2), 149-166. doi: 10.1007/s11414-009-9175-1

Rudasill, S. E., Sanaiha, Y., Mardock, A. L., Khoury, H., Xing, H., Antonios, J. W., McKinnell, J. A., & Benharash, P. (2019). Clinical outcomes of infective endocarditis in injection drug users. *Journal of the American College of Cardiology*, 73(5), 559-570. doi: <https://doi.org/10.1016/j.jacc.2018.10.082>

Ryan, R. (2016). Cochrane Consumers and Communication Group reviews: Meta-analysis. Cochrane handbook for systematic reviews of interventions; Melbourne, Australia: Cochrane Consumers and Communication: <http://cccg.cochrane.org>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Sanvisens, A., Hernández-Rubio, A., Zuluaga, P., Fuster, D., Papaseit, E., Galan, S., Farré, M., & Muga, R. (2021). Long-term outcomes of patients with cocaine use disorder: A 18-years addiction cohort study. *Frontiers in Pharmacology*, *12*(111), 625610. doi: 10.3389/fphar.2021.625610

Seitz, N.-N., Lochbühler, K., Atzendorf, J., Rauschert, C., Pfeiffer-Gerschel, T., & Kraus, L. (2019). Trends in substance use and related disorders: Analysis of the epidemiological survey of substance abuse 1995 to 2018. *Deutsches Arzteblatt International*, *116*(35-36), 585-591. doi: 10.3238/arztebl.2019.0585

Shapiro, M. F., Morton, S. C., McCaffrey, D. F., Senterfitt, J. W., Fleishman, J. A., Perlman, J. F., Athey, L. A., Keesey, J. W., Goldman, D. P., Berry, S. H., & Bozzette, S. A. (1999). Variations in the care of HIV-infected adults in the United States: Results from the HIV cost and services utilization study. *JAMA*, *281*(24), 2305-2315. doi: 10.1001/jama.281.24.2305

Solomon, L., Stein, M., Flynn, C., Schuman, P., Schoenbaum, E., Moore, J., Holmberg, S., & Graham, N. M. (1998). Health services use by urban women with or at risk for HIV-1 infection: The HIV Epidemiology Research Study (HERS). *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, *17*(3), 253-261. doi: 10.1097/00042560-199803010-00011

Sommers, I., Baskin, D., & Baskin-Sommers, A. (2006). Methamphetamine use among young adults: Health and social consequences. *Addictive Behaviors*, *31*(8), 1469-1476. doi: <https://doi.org/10.1016/j.addbeh.2005.10.004>

Sørup, C. M., Jacobsen, P., & Forberg, J. L. (2013). Evaluation of emergency department performance - a systematic review on recommended performance and quality-in-care measures. *Scandinavian*

1 *Journal of Trauma, Resuscitation and Emergency Medicine*, 21, 62. doi: 10.1186/1757-7241-21-
2 62

3

4 Stang, A. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of
5 nonrandomized studies in meta-analyses. *European Journal of Epidemiology*, 25(9), 603-605.
6 doi: 10.1007/s10654-010-9491-z

7

8 Stein, M. D., & Anderson, B. (2003). Injection frequency mediates health service use among persons with
9 a history of drug injection. *Drug and Alcohol Dependence*, 70(2), 159-168. doi: 10.1016/s0376-
10 8716(02)00344-7

11

12 Takahashi, T. A., Baernstein, A., Binswanger, I., Bradley, K., & Merrill, J. O. (2007). Predictors of
13 hospitalization for injection drug users seeking care for soft tissue infections. *Journal of General*
14 *Internal Medicine*, 22(3), 382-388. doi: 10.1007/s11606-006-0079-y

15

16 Trillo, A. D., Merchant, R. C., Baird, J. R., Liu, T., & Nirenberg, T. D. (2012). Sex differences in alcohol
17 misuse and estimated blood alcohol concentrations among emergency department patients:
18 Implications for brief interventions. *Academic Emergency Medicine*, 19(8), 924-933. doi:
19 10.1111/j.1553-2712.2012.01408.x

20

21 Tyndall, M. W., Patrick, D., Spittal, P., Li, K., O'Shaughnessy, M. V., & Schechter, M. T. (2002). Risky
22 sexual behaviours among injection drugs users with high HIV prevalence: Implications for STD
23 control. *Sexually Transmitted Infections*, 78(suppl 1), i170-i175.

24

25 Viechtbauer, W. (2010). Conducting meta-analyses in R with the metafor package. *Journal of Statistical*
26 *Software*, 36(3), 1-48. doi: 10.18637/jss.v036.i03

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Tables and figure legends:

Table 1: Study characteristics of ED use and hospitalization among PWID

Figure 1: PRISMA flow diagram

Figure 2: The pooled prevalence of emergency department use among people who inject drugs.

Figure 3: The pooled prevalence of hospitalization among people who inject drugs.

Figure 4: Pooled odds ratio of variables associated with emergency department use among people who inject drugs.

Figure 5: Pooled odds ratio of variables associated with hospitalization among people who inject drugs.

Supplementary File 1: Search strategy

Supplementary File 2: Risk of bias assessment using Newcastle-Ottawa Scale

Table 1: Study characteristics on emergency department (ED) use and hospitalization among people who inject drugs

ED use and hospitalization studies	Authors and year of publication	Years (y.) of data collections (number)	Sample at baseline	Final sample size and response rates	Country	Study Design	ED use/hospitalization/both	Diagnostic criteria used	Type of drug injection	Duration (months) of outcome measurements	Reason for ED use and hospitalization	Percentage of ED use / hospitalization		Socio-demographic determinants				Risky behaviors							Type of drug used	Service use variables																						
												ED use	Hospitalization	Being man	Being woman	Age <30 years	Higher education	Being employed	History of homelessness	History of physical abuse	Incarceration	Injecting >4 times/day	Duration of injection	Require assistance inject	Needle sharing	HIV-positive status	HCV-positive status	Soft tissue infection	Chronic physical illnesses	Non-injury-related diagnosis	Mechamphetamine use	Cocaine use	Cannabis use	Primary care services	Methadone maintenance treatment	Mental health services	Hospital referral	Nonurgent visits										
ED use studies (n=9)	Fairbairn et al., 2011	2005-2008 (4 y.)	437	428 98%	Canada	Cohort	ED use (Yes/no)	ICD-9 ^e	Heroin and cocaine	12	Any reason	64%						✓	✓																				✓									
	Marshall et al., 2012	1996 (1 y.)	427	427 100%	Canada	Cohort	ED use (Yes/no)	NA	Polydrug	12	Any reason	38%													✓	✓																						
	Lloyd-Smith et al., 2012	1997-2001 (5y.)	1083	1068 99%	Canada	Cohort	ED use (Yes/no)	ICD-10 ^f	Heroin and cocaine	48	Soft tissue infection	27%						✓																										✓				
	Palepu et al., 2003	2011 (1 y.)	444	350 79%	Canada	Cohort	ED use (Yes/no)	CAGE ^g	Polydrug	6	Alcohol use reason	29%										✓																										
	Knowlton et al., 2001	2006-2008 (3 y.)	287	287 100%	USA	Cohort	ED use (Yes/no)	NA	NA	6	HIV/AIDS infection	33%																																				

Journal Of Substance Use

	McDonald et al., 2011	41062	41062	UK	Cohort	Hospitalization (Yes/no)	ICD-9 ^e	NA	6	Alcohol use reason		8.1%		✓✓																	✓
	Nambiar et al., 2017	1995-2006 (12 y.)	1892	2106	Australia	Cohort	Frequent Hospitalization (Yes/no) ^c	ICD-10 ^f	Heroin or methamphetamine	12	Any reason		29%																		✓
ED use and hospitalization (n=3)	Stein & Anderson, 2003	2001-2002 (2 y.)	472	472	USA	Cohort	ED use and hospitalization (Yes/no)	DSM-III ^j	Heroin and cocaine	6	Any reason	34.5%	13.4%						✓✓										✓✓		
	Palepu et al., 1999	2001 (1 y.)	1103	1103	Canada	Cohort	ED use and hospitalization (Yes/no)	NA	Heroin and cocaine	6	Any reason	45%	21%	✓✓			✓✓							✓✓					✓✓	✓✓	
	Palepu et al., 2001	1997-1998 (2 y.)	598	598	Canada	Cohort	Frequent ED use and hospitalization (Yes/no) ^d	NA	cocaine	36	Any reason	60.2%	56.2%	✓✓			✓✓						✓✓					✓✓			

✓: All variables extracted from studies.

✓✓: Variables are retained in the final model after their inclusion in the meta-analysis.

a: Frequent ED use is defined as 3+ visits in a 12-month period.

b: Frequent ED use is defined as 3+ visits in a 2-years period.

c: Frequent hospitalizations is defined as 2+ stays in a 12-month period.

d: Frequent ED use is defined as 3+ visits and frequent hospitalizations as 2+ stays in the 3-year study period.

e: International Classification of Diseases, Ninth Revision

f: International Classification of Diseases, Tenth Revision

g: Screening tool for diagnosis of alcohol use disorders

h: The Alcohol Use Disorders Identification Test-Concise

i: Addiction Severity Index

j: Diagnostic and Statistical Manual of Mental Disorders, Third Edition

FOR PEER REVIEW

Figure 1: PRISMA flow diagram




Figure 2: The pooled prevalence of emergency department use among people who inject drugs




Figure 3: The pooled prevalence of hospitalization among people who inject drugs




Figure 4: Pooled odds ratio of variables associated with emergency department use among people who inject drugs





Figure 5: Pooled odds ratio of variables associated with hospitalization among people who inject drugs



Supplementary File 1: Search strategy

Database	Key words
PubMed	<p>#27 ((((((((((Ambulatory Care[MeSH Terms]) OR (Inpatients[MeSH Terms])) OR (Health Services Administration[MeSH Terms])) OR (Health Services Accessibility[MeSH Terms])) OR (Emergency Medical Services[MeSH Terms])) OR (Emergency Service, Hospital[MeSH Terms])) OR (("access"[All Fields] OR "accessed"[All Fields] OR "accesses"[All Fields] OR "accessibilities"[All Fields] OR "accessibility"[All Fields] OR "accessible"[All Fields] OR "accessing"[All Fields]) AND "to general practitioner"[Title/Abstract])) OR (General Practitioners[MeSH Terms])) OR (Hospitalization[MeSH Terms])) AND (((((((((((((((((((Injecting drug use[Title/Abstract]) OR (injection drug[Title/Abstract])) OR (injected drug use[Title/Abstract])) OR (inject drug use[Title/Abstract])) OR (People who inject drugs[Title/Abstract])) OR (PWID[Title/Abstract])) OR (Substance-Related Disorders[MeSH Terms])) OR (Substance Abuse, Intravenous[MeSH Terms])) OR (injecting cocaine[Title/Abstract])) OR (injecting cocaine[Title/Abstract])) OR (inject methamphetamine[Title/Abstract])) OR (injecting heroin[Title/Abstract])) OR (Morphine injection[Title/Abstract])) OR (opioid injection[Title/Abstract])) OR (Injecting Heroin[Title/Abstract])) OR (Morphine injection[Title/Abstract])) OR (opioid injection[Title/Abstract])) OR (Ativan Injection[Title/Abstract])) OR (benzodiazepine injection[Title/Abstract]))</p> <p>#26 ((((((((((Ambulatory Care[MeSH Terms]) OR (Inpatients[MeSH Terms])) OR (Health Services Administration[MeSH Terms])) OR (Health Services Accessibility[MeSH Terms])) OR (Emergency Medical Services[MeSH Terms])) OR (Emergency Service, Hospital[MeSH Terms])) OR (("access"[All Fields] OR "accessed"[All Fields] OR "accesses"[All Fields] OR "accessibilities"[All Fields] OR "accessibility"[All Fields] OR "accessible"[All Fields] OR "accessing"[All Fields]) AND "to general practitioner"[Title/Abstract])) OR (General Practitioners[MeSH Terms])) OR (Hospitalization[MeSH Terms]))</p> <p>#25 (((((((((((((((((((Injecting drug use[Title/Abstract]) OR (injection drug[Title/Abstract])) OR (injected drug use[Title/Abstract])) OR (inject drug use[Title/Abstract])) OR (People who inject drugs[Title/Abstract])) OR (PWID[Title/Abstract])) OR (Substance-Related Disorders[MeSH Terms])) OR (Substance Abuse, Intravenous[MeSH Terms])) OR (injecting cocaine[Title/Abstract])) OR (injecting cocaine[Title/Abstract])) OR (inject methamphetamine[Title/Abstract])) OR (injecting heroin[Title/Abstract])) OR (Morphine injection[Title/Abstract])) OR (opioid injection[Title/Abstract])) OR (Injecting Heroin[Title/Abstract])) OR (Morphine injection[Title/Abstract])) OR (opioid injection[Title/Abstract])) OR (Ativan Injection[Title/Abstract])) OR (benzodiazepine injection[Title/Abstract]))</p> <p>#24 Hospitalization[MeSH Terms]</p> <p>#23 General Practitioners[MeSH Terms]</p> <p>#22 Emergency Service, Hospital[MeSH Terms]</p>

	<p>#21 Emergency Medical Services[MeSH Terms] #20 Health Services Accessibility[MeSH Terms] #19 Health Services Administration[MeSH Terms] #18 Inpatients[MeSH Terms] #17 Ambulatory Care[MeSH Terms] #16 benzodiazepine injection[Title/Abstract] #15 Ativan Injection[Title/Abstract] #14 Injecting Heroin[Title/Abstract] #13 opioid injection[Title/Abstract] #12 Morphine injection[Title/Abstract] #11 injecting heroin[Title/Abstract] #10 inject methamphetamine[Title/Abstract] #9 injecting cocaine[Title/Abstract] #8 Substance Abuse, Intravenous[MeSH Terms] #7 Substance-Related Disorders[MeSH Terms] #6 PWID[Title/Abstract] #5 People who inject drugs[Title/Abstract] #4 inject drug use[Title/Abstract] #3 injected drug use[Title/Abstract] #2 injection drug[Title/Abstract] #1 Injecting drug use[Title/Abstract]</p>
<p>Scopus</p>	<p>#1 TITLE-ABS-KEY (injecting AND drug AND use) #2 TITLE-ABS-KEY (injection AND drug) #3 TITLE-ABS-KEY (injected AND drug AND use) #4 TITLE-ABS-KEY (inject AND drug AND use) #5 TITLE-ABS-KEY (people AND who AND inject AND drugs) #6 TITLE-ABS-KEY (pwid) #7 TITLE-ABS-KEY (substance-related AND disorders) #8 TITLE-ABS-KEY (substance AND abuse, AND intravenous) #9 TITLE-ABS-KEY (injecting AND cocaine) #10 TITLE-ABS-KEY (inject AND methamphetamine) #11 TITLE-ABS-KEY (injecting AND heroin) #12 TITLE-ABS-KEY (morphine AND injection) #13 TITLE-ABS-KEY (opioid AND injection) #14 TITLE-ABS-KEY (injecting AND heroin) #15 TITLE-ABS-KEY (ativan AND injection) #16 TITLE-ABS-KEY (benzodiazepine AND injection) #17 TITLE-ABS-KEY (ambulatory AND care) #18 TITLE-ABS-KEY (inpatients) #19 TITLE-ABS-KEY (health AND services AND administration) #20 TITLE-ABS-KEY (health AND services AND accessibility) #21 TITLE-ABS-KEY (emergency AND medical AND services) #22 TITLE-ABS-KEY (emergency AND service, AND hospital) #23 TITLE-ABS-KEY (general AND practitioners) #24 TITLE-ABS-KEY (hospitalization)</p>

	<p>#25 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 #26 #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 #27 #25 AND #26S</p>
Web of Knowledge	<p>TS=(Injecting drug use OR injection drug OR injected drug use OR inject drug use OR People who inject drugs OR PWID OR Substance-Related Disorders OR Substance Abuse, Intravenous OR injecting cocaine OR inject methamphetamine OR injecting heroin OR Morphine injection OR opioid injection OR Ativan Injection OR benzodiazepine injection) AND TS=(Ambulatory Care OR Inpatients OR Health Services Administration OR Health Services Accessibility OR Emergency Medical Services OR Emergency Service, Hospital OR General Practitioners OR Hospitalization)</p>
Cochrane	<p>#1 ("injecting drug use"):ti,ab,kw #2 (injection drug):ti,ab,kw #3 (injected drug use):ti,ab,kw #4 (People who inject drugs):ti,ab,kw #5 (PWID):ti,ab,kw #6 MeSH descriptor: [Substance-Related Disorders] explode all trees #7 MeSH descriptor: [Substance Abuse, Intravenous] explode all trees #8 (injecting cocaine):ti,ab,kw #9 (inject methamphetamine):ti,ab,kw #10 (injecting heroin):ti,ab,kw #11 (Morphine injection):ti,ab,kw #12 (opioid injection):ti,ab,kw #13 (Injecting Heroin):ti,ab,kw #14 (Ativan Injection):ti,ab,kw #15 (benzodiazepine injection):ti,ab,kw #16 MeSH descriptor: [Ambulatory Care] explode all trees #17 MeSH descriptor: [Inpatients] explode all trees #18 MeSH descriptor: [Outpatients] explode all trees #19 MeSH descriptor: [Health Services Administration] explode all trees #20 MeSH descriptor: [Health Services Accessibility] explode all trees #21 MeSH descriptor: [Emergency Medical Services] explode all trees #22 MeSH descriptor: [Emergency Service, Hospital] explode all trees #23 MeSH descriptor: [General Practitioners] explode all trees #24 MeSH descriptor: [Hospitalization] in all MeSH products #25 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 #26 #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 #27 #25 AND #26</p>

Supplementary File 2: Risk of bias assessment using Newcastle-Ottawa Scale

Study	Selection (***●)	Comparability (*)	Exposure/outcome (*●●)	Method of assessment	Quality Assessment
Fairbairn et al., 2011	**	*	*●●	Newcastle-Ottawa Scale adapted for cohort studies	Good
Nambiar et al., 2017	***●	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Very Good
Nambiar et al., 2017	*	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Satisfactory
Kerr et al., 2004	**●	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Good
Marshall et al., 2012	**●		*●●	Newcastle-Ottawa Scale adapted for cohort studies	Good
Lloyd-Smith et al., 2012	**●●	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Very Good
Palepu et al., 1999	**●	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Good
Palepu et al., 2001	**●	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Good
Palepu et al., 2003	***●	*	*●●	Newcastle-Ottawa Scale adapted for cohort studies	Very Good
Knowlton et al., 2001	***●	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Very Good
Stein & Anderson, 2003	***		*	Newcastle-Ottawa Scale adapted for cohort studies	Satisfactory
Islam et al., 2013	**	*	*	Newcastle-Ottawa Scale adapted for	Good

				cross-sectional studies	
Hope et al., 2015	***	*	*	Newcastle-Ottawa Scale adapted for cohort studies	Very Good
Binswanger et al., 2008	**●	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Good
Nambiar et al., 2017	***●	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Very Good
Olubamwo et al., 2018	***●	*	*	Newcastle-Ottawa Scale adapted for cohort studies	Good
Takahashi et al., 2006	***●	*	*●	Newcastle-Ottawa Scale adapted for cohort studies	Very Good
Lloyd-Smith et al., 2010	**	*	**	Newcastle-Ottawa Scale adapted for cohort studies	Satisfactory
McDonald et al., 2011	**	*	**	Newcastle-Ottawa Scale adapted for cohort studies	Satisfactory

*: For cross-section studies

●: For cohort studies